Biotechnology & Medical Research

Nymox Pharmaceutical Corp announces prostate cancer clinical trial results from completed 18 month endpoint study

Nymox Pharmaceutical Corp:Announces prostate cancer clinical trial results from completed 18 month endpoint study.Says the study successfully met its pre-determined endpoints.Says cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.

10:00am EST

Bellerophon Therapeutics announces positive data from the final analysis of the Phase 2 long-term extension study of INOpulse

Bellerophon Therapeutics Inc:Bellerophon Therapeutics announces positive data from the final analysis of the phase 2 long-term extension study of inopulse for treatment of pulmonary arterial hypertension.Says for patients in the long-term extension study, no significant safety issues have been...

8:03am EST

Immune Design posts positive data from three clinical trials of immuno-oncology product candidates

Immune Design Corp:Reported positive topline data from three ongoing Phase 1 oncology studies.Says CMB305 was safe, without dose-limiting toxicities, as reviewed by an independent data safety monitoring board.

8:00am EST

Actelion Ltd to propose increased dividend

Actelion Ltd:Board to propose increased dividend of CHF 1.50 per share.

1:00am EST

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider : Edison Investment Research
$10.00
Provider : Edison Investment Research
$10.00
Provider : Edison Investment Research
$10.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.